Research graph
References from Evaluation of eravacycline susceptibility testing by MIC test strip and disk diffusion against broth microdilution in carbapenem-resistant Enterobacterales. Local targets link to admitted publications; unresolved targets remain external evidence.
Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City
10.1128/aac.04809-14 · 2015 · External reference
Evaluation of eravacycline: a novel fluorocycline
10.1002/phar.2366 · 2020 · External reference
Multicenter clinical evaluation of ETEST eravacycline for susceptibility testing of Enterobacteriaceae and Enterococci
10.1128/jcm.01650-22 · 2023 · External reference
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
10.1016/s1473-3099(18)30605-4 · 2019 · External reference
In vitro activities of aztreonam-avibactam, eravacycline, cefoselis, and other comparators against clinical Enterobacterales isolates: a multicenter study in Chin
10.1128/spectrum.04873-22 · 2023 · External reference
Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET Antimicrobial Resistance Surveillance Program 2025
10.1186/s44280-025-00092-0 · 2026 · External reference
Verification of commercial microbial identification and antimicrobial susceptibility testing systems
2015 · External reference
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 12th ed
2024 · External reference
Performance standards for antimicrobial disk susceptibility tests, 14th ed
2024 · External reference
Performance standards for antimicrobial susceptibility testing, 36th ed
2026 · External reference
Resistance of Gram-negative bacteria to eravacycline: a systematic review of data from in vitro studies
10.3390/pathogens14121214 · 2025 · External reference
Response to STMA request for changes to the document titled, Guidance for Industry and FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems
2015 · External reference
In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020
10.1016/j.jgar.2023.04.017 · 2023 · External reference
Eravacycline: the tetracyclines strike back
10.1177/1060028019850173 · 2019 · External reference
Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus
10.1093/jac/dkae220 · 2024 · External reference
Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion
10.1093/jac/dkae426 · 2025 · External reference
Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy
10.1016/j.micres.2022.127249 · 2023 · External reference
Multidrug-resistant Gram-negative bacterial infections
10.1016/s0140-6736(24)02081-6 · 2025 · External reference
In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017
10.1128/aac.01699-19 · 2020 · External reference
Specifications for antimicrobial susceptibility testing of eravacycline, (2025)
10.3760/cma.j.cn114452-20250211-00074 · 2025 · External reference
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)
10.1016/j.cmi.2021.11.025 · 2022 · External reference
Carbapenem-resistant Enterobacteriaceae: global action required
10.1016/s1473-3099(19)30210-5 · 2019 · External reference
Comparative evaluation of disc diffusion, Liofilchem™ MTS strips, Etest® Biomérieux with broth microdilution for eravacylin susceptibility testing
10.1093/jac/dkag248 · 2026 · External reference
The WHO bacterial priority pathogens list 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance
10.1016/s1473-3099(25)00118-5 · 2025 · External reference
Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial
10.1001/jamasurg.2016.4237 · 2017 · External reference
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens
10.1128/aac.01288-13 · 2013 · External reference
Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections
10.1093/cid/ciae403 · 2024 · External reference
The natural history of carbapenemase-producing Enterobacterales: progression from carriage of various carbapenemases to bloodstream infection
10.1093/cid/ciae110 · 2024 · External reference
Unresolved reference
External reference
Eravacycline-injection products
2022 · External reference
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
10.1093/jac/dkaf502 · 2026 · External reference
Comparison of disk diffusion, MIC test strip and broth microdilution methods for eravacycline susceptibility testing
10.1016/j.cmi.2025.04.014 · 2025 · External reference
In vitro susceptibility of beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline
10.1038/ja.2016.73 · 2016 · External reference
In vitro activities of eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China
10.1186/s12879-019-4093-1 · 2019 · External reference
Antibacterial activity of eravacycline against carbapenem-resistant Gram-negative isolates in China: an in vitro study
10.2147/idr.s396910 · 2023 · External reference
Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial
10.1001/jamasurg.2016.4237 · ExternalCitation · doi-reference
Evaluation of eravacycline: a novel fluorocycline
10.1002/phar.2366 · ExternalCitation · doi-reference
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)
10.1016/j.cmi.2021.11.025 · ExternalCitation · doi-reference
Comparison of disk diffusion, MIC test strip and broth microdilution methods for eravacycline susceptibility testing
10.1016/j.cmi.2025.04.014 · ExternalCitation · doi-reference
In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020
10.1016/j.jgar.2023.04.017 · ExternalCitation · doi-reference
Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy
10.1016/j.micres.2022.127249 · ExternalCitation · doi-reference
Multidrug-resistant Gram-negative bacterial infections
10.1016/s0140-6736(24)02081-6 · ExternalCitation · doi-reference
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
10.1016/s1473-3099(18)30605-4 · ExternalCitation · doi-reference
Carbapenem-resistant Enterobacteriaceae: global action required
10.1016/s1473-3099(19)30210-5 · ExternalCitation · doi-reference
The WHO bacterial priority pathogens list 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance
10.1016/s1473-3099(25)00118-5 · ExternalCitation · doi-reference
In vitro susceptibility of beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline
10.1038/ja.2016.73 · ExternalCitation · doi-reference
The natural history of carbapenemase-producing Enterobacterales: progression from carriage of various carbapenemases to bloodstream infection
10.1093/cid/ciae110 · ExternalCitation · doi-reference
Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections
10.1093/cid/ciae403 · ExternalCitation · doi-reference
Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus
10.1093/jac/dkae220 · ExternalCitation · doi-reference
Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion
10.1093/jac/dkae426 · ExternalCitation · doi-reference
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
10.1093/jac/dkaf502 · ExternalCitation · doi-reference
Comparative evaluation of disc diffusion, Liofilchem™ MTS strips, Etest® Biomérieux with broth microdilution for eravacylin susceptibility testing
10.1093/jac/dkag248 · ExternalCitation · doi-reference
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens
10.1128/aac.01288-13 · ExternalCitation · doi-reference
In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017
10.1128/aac.01699-19 · ExternalCitation · doi-reference
Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City
10.1128/aac.04809-14 · ExternalCitation · doi-reference
Multicenter clinical evaluation of ETEST eravacycline for susceptibility testing of Enterobacteriaceae and Enterococci
10.1128/jcm.01650-22 · ExternalCitation · doi-reference
In vitro activities of aztreonam-avibactam, eravacycline, cefoselis, and other comparators against clinical Enterobacterales isolates: a multicenter study in Chin
10.1128/spectrum.04873-22 · ExternalCitation · doi-reference
Eravacycline: the tetracyclines strike back
10.1177/1060028019850173 · ExternalCitation · doi-reference
In vitro activities of eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China
10.1186/s12879-019-4093-1 · ExternalCitation · doi-reference
Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET Antimicrobial Resistance Surveillance Program 2025
10.1186/s44280-025-00092-0 · ExternalCitation · doi-reference
Antibacterial activity of eravacycline against carbapenem-resistant Gram-negative isolates in China: an in vitro study
10.2147/idr.s396910 · ExternalCitation · doi-reference
Resistance of Gram-negative bacteria to eravacycline: a systematic review of data from in vitro studies
10.3390/pathogens14121214 · ExternalCitation · doi-reference
Specifications for antimicrobial susceptibility testing of eravacycline, (2025)
10.3760/cma.j.cn114452-20250211-00074 · ExternalCitation · doi-reference
